Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model.

Furthermore, this mechanism seems quite significant because a different protocol, administering the most active enantiomer of AXX71 (compound AXX13, IC 50 values of 6 nM and 109 nM on human and mouse P2X7, respectively, and inactive on human P2Xs and P2Ys receptors and mouse P2X4, data generated by Axxam SpA, see Table 1 ) at the lower dose of 15 mg/kg intraperitoneally, but twice a day, with the aim of prolonging target coverage ( Figure 2 ), did not cause P2X7 protein downregulation ( Figure 2 F), but it was unable to sustain the transitory improvement in motor abilities and muscle strength ( Figure 2 A–D).

also in 5,695 other papers